Delcath Systems (Nasdaq: DCTH) reported a sharp year-over-year revenue increase in Q1 2025, driven by growing commercial adoption of its liver-directed cancer therapies. Total revenue…
Delcath Systems (Nasdaq: DCTH) reported a sharp year-over-year revenue increase in Q1 2025, driven by growing commercial adoption of its liver-directed cancer therapies. Total revenue…